- Record: found
- Abstract: not found
- Article: not found
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Johnny Mahlangu
1 ,
Johannes Oldenburg
1 ,
Ido Paz-Priel
1 ,
Claude Negrier
1 ,
Markus Niggli
1 ,
M. Elisa Mancuso
1 ,
Christophe Schmitt
1 ,
Victor Jiménez-Yuste
1 ,
Christine Kempton
1 ,
Christophe Dhalluin
1 ,
Michael U. Callaghan
1 ,
Willem Bujan
1 ,
Midori Shima
1 ,
Joanne I. Adamkewicz
1 ,
Elina Asikanius
1 ,
Gallia G. Levy
1 ,
Rebecca Kruse-Jarres
1
August 30 2018
August 30 2018
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and
factor X to replace the function of missing activated factor VIII, thereby restoring
hemostasis. In a phase 3, multicenter trial, we investigated its use as prophylaxis
in persons who have hemophilia A without factor VIII inhibitors.